Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01357330 | Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors | PHASE1 | COMPLETED | 18 | — | — | May 1, 2011 | Jun 1, 2012 | Apr 1, 2016 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Dose escalation phase The starting dose of SAR245408 will be 25-mg once daily (up to 200-mg). The starting dose of MSC1936369B will be 15- mg once daily (up to 90-mg) |
| Name | Type | Description |
|---|---|---|
| SAR245408 (XL147) | DRUG | Pharmaceutical form:capsule and tablet Route of administration: oral |
| MSC1936369B | DRUG | Pharmaceutical form:capsule Route of administration: oral |
Inclusion criteria: Patient with advanced solid tumors for which there is no approved or curative therapy: * has any advanced solid tumor with diagnosed alteration in 1 or more genes of the PI3K, and mitogen-activated protein kinase (MAPK) pathways and/or * has a histologically or cytologically co...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |